Assessment of functional effects of unclassified genetic variants
Open Access
- 24 October 2008
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 29 (11), 1314-1326
- https://doi.org/10.1002/humu.20899
Abstract
Inherited predisposition to disease is often linked to reduced activity of a disease associated gene product. Thus, quantitation of the influence of inherited variants on gene function can potentially be used to predict the disease relevance of these variants. While many disease genes have been extensively characterized at the functional level, few assays based on functional properties of the encoded proteins have been established for the purpose of predicting the contribution of rare inherited variants to disease. Much of the difficulty in establishing predictive functional assays stems from the technical complexity of the assays. However, perhaps the most challenging aspect of functional assay development for clinical testing purposes is the absolute requirement for validation of the sensitivity and specificity of the assays and the determination of positive predictive values (PPVs) and negative predictive values (NPVs) of the assays relative to a “gold standard” measure of disease predisposition. In this commentary, we provide examples of some of the functional assays under development for several cancer predisposition genes (BRCA1, BRCA2, CDKN2A, and mismatch repair [MMR] genes MLH1, MSH2, MSH6, and PMS2) and present a detailed review of the issues associated with functional assay development. We conclude that validation is paramount for all assays that will be used for clinical interpretation of inherited variants of any gene, but note that in certain circumstances information derived from incompletely validated assays may be valuable for classification of variants for clinical purposes when used to supplement data derived from other sources. Hum Mutat 29(11), 1314–1326, 2008.Keywords
This publication has 96 references indexed in Scilit:
- Prediction and assessment of splicing alterations: implications for clinical testingHuman Mutation, 2008
- Genetic evidence and integration of various data sources for classifying uncertain variants into a single modelHuman Mutation, 2008
- In silico analysis of missense substitutions using sequence-alignment based methodsHuman Mutation, 2008
- Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genesHuman Mutation, 2008
- Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test resultsHuman Mutation, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Direct Visualization of Asymmetric Adenine Nucleotide-Induced Conformational Changes in MutLαMolecular Cell, 2008
- Mechanisms and functions of DNA mismatch repairCell Research, 2007
- A Systematic Genetic Assessment of 1,433 Sequence Variants of Unknown Clinical Significance in the BRCA1 and BRCA2 Breast Cancer–Predisposition GenesAmerican Journal of Human Genetics, 2007
- Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibitionNature, 1995